Truist Raises Vertex (VRTX) Price Target Following Phase 3 Trial Results

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high profit margin stocks to buy. On March 10, Truist Securities boosted its price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $525 from $490, while keeping a Buy rating on the company’s shares. The firm cited encouraging Week-36 interim findings from Vertex’s Phase 3 RAINIER study in IgAN. The trial satisfied all primary and secondary objectives, demonstrating deep, consistent answers across subgroups and a strong ...